performed a comparative single-cell analysis of immune cell dynamics in triple-negative breast cancer patients treated with paclitaxel, nab-paclitaxel, and their combinations with the anti-PD-L1 antibody atezolizumab, providing a detailed view of immune cell transitions during immunotherapy (24). The gene discussed is CD274; the disease is triple-negative breast carcinoma.